Circulating Tumor HPV DNA in Patients With Head and Neck Carcinoma

被引:5
|
作者
Mijares, Kevin [1 ]
Ferrandino, Rocco [2 ]
Chai, Raymond [2 ]
Roof, Scott [2 ]
Bhardwaj, Swati [3 ]
Posner, Marshall [4 ]
Westra, William H. [3 ,5 ]
机构
[1] Mt Sinai West, Dept Pathol, New York, NY USA
[2] Mt Sinai Hosp, Dept Otolaryngol Head & Neck Surg, Icahn Sch Med, New York, NY USA
[3] Mt Sinai Hosp, Dept Pathol, Icahn Sch Med, New York, NY USA
[4] Mt Sinai Hosp, Icahn Sch Med, Dept Med, Div Hematol & Med Oncol, New York, NY USA
[5] 1468 Madison Ave,Annenberg Bldg 15-54, New York, NY 10029 USA
关键词
liqued biopsy; HPV-associated head and neck cancer; oropharyngeal squamous cell carcinoma; human papillomavirus; NavDx; HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CARCINOMA; SURROGATE MARKER; PLASMA; CANCER; SYSTEM;
D O I
10.1097/PAS.0000000000002134
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Circulating tumor human papillomavirus DNA (ctHPVDNA) testing using digital-droplet polymerase chain reaction (PCR) detects fragments of tumor-modified human papillomavirus (HPV) in the plasma of patients with HPV-associated head and neck squamous cell carcinomas (HNSCCs). Its impact on tumor surveillance and primary diagnosis is limited by unresolved issues relating to sensitivity and specificity. The study population consisted of patients with HNSCC who had undergone ctHPVDNA testing. HPV status was determined by p16 immunohistochemistry and PCR-HPV genotyping on the tumor samples. For discrepant cases (HPV-positive/ctHPVDNA-negative), HPV status was confirmed by RNA in situ hybridization and, when possible, targeted single-nucleotide polymorphisms genotyping. A total of 167 patients had ctHPVDNA testing, and 141 tumors were HPV positive by p16 immunohistochemistry and PCR genotyping. Genotypes included types 16 (91.5%), 33 (4.3%), 35 (2.1%), and 18 (2.1%). ctHPVDNA was detected in 133 (94.3%) of HPV-positive HNSCCs but in none of the HPV-negative HNSCCs. Four of the 5 p16-positive cases that were negative by PCR and ctHPVDNA were positive by RNA in situ hybridization, and in 2 of these cases, rare high-risk genotypes were identified. ctHPVDNA had a sensitivity of 91.7%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 63.6%. The likelihood that patients with HPV-positive HNSCC have detectable ctHPVDNA is high. Non-HPV16 genotypes contribute to discrepancies but only in a small subset of cases. This finding validates ongoing efforts to use ctHPVDNA as a surveillance tool, and even as a primary diagnostic assay in patients presenting with masses in the neck and/or oropharynx.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 50 条
  • [1] Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
    Brandt, Anna
    Thiele, Benjamin
    Schultheiss, Christoph
    Daetwyler, Eveline
    Binder, Mascha
    CANCERS, 2023, 15 (07)
  • [2] Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA
    Dermody, Sarah M.
    Haring, Catherine T.
    Bhambhani, Chandan
    Tewari, Muneesh
    Brenner, J. Chad
    Swiecicki, Paul L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (03)
  • [3] Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA
    Sarah M Dermody
    Catherine T Haring
    Chandan Bhambhani
    Muneesh Tewari
    J Chad Brenner
    Paul L Swiecicki
    Current Treatment Options in Oncology, 2021, 22
  • [4] Circulating Tumor HPV DNA in Patients With Stage I and II HPV-Associated Head and Neck Cancer After Surgery
    Naegele, Saskia
    Das, Dipon
    Hirayama, Shun
    Shalhout, Sophia
    Lee, Hang
    Richmon, Jeremy
    Faden, Daniel
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2024, 150 (06) : 521 - 523
  • [5] Association of circulating tumor HPV16DNA levels and quantitative PET parameters in patients with HPV-positive head and neck squamous cell carcinoma
    Tatsumi, Mitsuaki
    Tanaka, Hidenori
    Takenaka, Yukinori
    Suzuki, Motoyuki
    Fukusumi, Takahito
    Eguchi, Hirotaka
    Watabe, Tadashi
    Kato, Hiroki
    Yachida, Shinichi
    Inohara, Hidenori
    Tomiyama, Noriyuki
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [6] Association of circulating tumor HPV16DNA levels and quantitative PET parameters in patients with HPV-positive head and neck squamous cell carcinoma
    Mitsuaki Tatsumi
    Hidenori Tanaka
    Yukinori Takenaka
    Motoyuki Suzuki
    Takahito Fukusumi
    Hirotaka Eguchi
    Tadashi Watabe
    Hiroki Kato
    Shinichi Yachida
    Hidenori Inohara
    Noriyuki Tomiyama
    Scientific Reports, 14
  • [7] Detection of circulating tumor DNA in operable locoregionally advanced HPV-negative head and neck squamous cell carcinoma
    Beaussire, L.
    Berghian, A.
    Bohers, E.
    Viennot, M.
    Libraire, J.
    Mardion, N. Bon
    Meret, E.
    Obongo, R.
    Sarafan-vasseur, N.
    Di Fiore, F.
    Clatot, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S563 - S563
  • [8] Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
    Nobuyuki Chikuie
    Yuji Urabe
    Tsutomu Ueda
    Takao Hamamoto
    Takayuki Taruya
    Takashi Kono
    Kohei Yumii
    Sachio Takeno
    Scientific Reports, 12
  • [9] Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
    Chikuie, Nobuyuki
    Urabe, Yuji
    Ueda, Tsutomu
    Hamamoto, Takao
    Taruya, Takayuki
    Kono, Takashi
    Yumii, Kohei
    Takeno, Sachio
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [10] Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
    Kogo, Ryunosuke
    Manako, Tomomi
    Iwaya, Takeshi
    Nishizuka, Satoshi
    Hiraki, Hayato
    Sasaki, Yasushi
    Idogawa, Masashi
    Tokino, Takashi
    Koide, Ayaka
    Komune, Noritaka
    Yasumatsu, Ryuji
    Nakagawa, Takashi
    CANCER MEDICINE, 2022, 11 (21): : 3960 - 3968